Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1995-09-15
1997-02-04
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
514824, A61K 31135
Patent
active
055998445
ABSTRACT:
TGF-beta activators and TGF-beta production stimulators are employed to prevent or treat conditions characterized by inappropriate proliferation of smooth muscle cells, such as the prevention or reduction of restenosis following angioplasty or other vascular trauma. Such TGF-beta activators and production stimulators inhibit abnormal proliferation of smooth muscle cells. TGF-beta activators or production stimulators that are not characterized by an undesirable systemic toxicity profile at a prophylactic dose are also amenable to chronic use for prophylactic purposes with respect to disease states involving proliferation of vascular smooth muscle cells over time. Further provided is a method for upregulating cellular mRNA coding for TGF-beta.
REFERENCES:
patent: 4235988 (1980-11-01), Fildes et al.
patent: 4442119 (1984-04-01), Magarian et al.
patent: 4824436 (1989-04-01), Wolinsky
patent: 4826672 (1989-05-01), Milius et al.
patent: 4839155 (1989-06-01), McCague
patent: 4859585 (1989-08-01), Sonnenschein et al.
patent: 4879315 (1989-11-01), Magarian et al.
patent: 4973755 (1990-11-01), Grafe et al.
patent: 4990538 (1991-02-01), Harris et al.
patent: 4997652 (1991-03-01), Wong
patent: 5015666 (1991-05-01), Magarian et al.
patent: 5032679 (1991-07-01), Brandley et al.
patent: 5047431 (1991-09-01), Schickaneder et al.
patent: 5049132 (1991-09-01), Shaffer et al.
patent: 5098903 (1992-03-01), Magarian et al.
patent: 5112305 (1992-05-01), Barath et al.
patent: 5120535 (1992-06-01), Marquardt et al.
patent: 5140012 (1992-08-01), McGovern et al.
patent: 5166143 (1992-11-01), Ondetti et al.
patent: 5171217 (1992-12-01), March et al.
patent: 5189046 (1993-02-01), Burch et al.
patent: 5192525 (1993-03-01), Yang et al.
patent: 5208019 (1993-05-01), Hannson et al.
patent: 5216024 (1993-06-01), Markaverich et al.
patent: 5219548 (1993-06-01), Yang et al.
patent: 5221620 (1993-06-01), Purchio et al.
patent: 5238950 (1993-08-01), Clader et al.
patent: 5242397 (1993-09-01), Barath et al.
patent: 5268358 (1993-12-01), Fretto
patent: 5280016 (1994-01-01), Conrad et al.
patent: 5280109 (1994-01-01), Miyazono et al.
patent: 5283257 (1994-02-01), Gregory et al.
patent: 5284763 (1994-02-01), Derynk et al.
patent: 5288711 (1994-02-01), Mitchell et al.
patent: 5304325 (1994-04-01), Kaufman et al.
patent: 5304541 (1994-04-01), Purchio et al.
patent: 5308622 (1994-05-01), Casscells et al.
patent: 5308862 (1994-05-01), Ohlstein
patent: 5324736 (1994-06-01), Magarian et al.
patent: 5326757 (1994-07-01), Demopoulos
patent: 5356713 (1994-10-01), Charmot et al.
patent: 5362424 (1994-11-01), Lee et al.
patent: 5380716 (1995-01-01), Conrad et al.
patent: 5385935 (1995-01-01), Tamai et al.
patent: 5391577 (1995-02-01), Cullinan et al.
patent: 5393763 (1995-02-01), Black et al.
patent: 5453436 (1995-09-01), Ohlstein
patent: 5468746 (1995-11-01), Casagrande et al.
patent: 5472985 (1995-12-01), Grainger et al.
patent: 5482949 (1996-01-01), Black et al.
patent: 5491173 (1996-02-01), Toivola et al.
Attwood et al., "A Light Scattering Study on Oil-In-Water Microemulsions", International Journal of Pharmaceutics, 52, 165-171 (1989).
Bagdade et al., "Effects of Tamoxifen Treatment on Plasma Lipids and Lipoprotein Lipid Composition", J. Clinical Endocrinology and Metabolism, 70, 1132-1135 (1990).
Barath et al., "Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury", JACC, 13, 252A, Abstract No. 252A (Feb. 1989).
Bertelli et al., "Adjuvant Tamoxifen in Primary Breast Cancer: Influence on Plasma Lipids and Antithrombin III Levels", Breast Cancer Res. and Treatment, 12, 307-310 (1988).
Bruengger et al., "Smooth Muscle Cell of the Canine Prostate in Spontaneous Benign Hyperplasia, Steroid Induced Hyperplasia and Estrogen or Tamoxifen Treated Dogs", J. Urology, 130, 1208-1210 (Dec. 1983).
Bruning et al., "Tamoxifen, Serum Lipoproteins and Cardiovascular Risk", Br. J. Cancer, 58, 497-499 (1988).
Butta et al., "Induction of Transforming Growth Factors .beta..sub.1 in Human Breast Cancer in Vivo Following Tamoxifen Treatment ", Cancer Res., 52, 4261-4264 (Aug. 1, 1992).
Craig et al., "Modern Pharmacology", Little Brown and Company, p. 399 (1982).
Dimond et al., "TGF-.beta. Shows Potential as Therapeutic Agent for Macular Holes", Genetic Eng. News, 7, 19 (Feb. 1, 1993).
Fanelli et al., "Restenosis Following Coronary Angioplasty", Amer. Heart J., 119, 357-368 (Feb. 1990).
Farhat et al., "In Vitro Effect of Oestradiol on Thymidine Uptake in Pulmonary Vascular Smooth Muscle Cell: Role of the Endothelium", Br. J. Pharamcol., 107, 679-683 (1992).
Fischer et al., "A Possible Mechanism in Arterial Wall for Mediation of Sex Difference in Atherosclerosis," Experimental and Molecular Pathology, 43, 288-296 (1985).
Forrester et al., "A Paradigm for Restenosis Based on Cell Biology: Clues for the Development of New Preventive Therapies", JACC, 17, 758-769 (Mar. 1, 1991).
Gasco et al., "In Vitro Permeation of Azelaic Acid From Viscoized Microemulsions", Int'l J. of Pharmaceutics, 69, pp. 193-196 (1991).
Grainger et al., "Hexamethylenebisacetamide Selectively Inhibits the Proliferation of Human and Rat Vascular Smooth-Muscle Cells", Biochem J., 283, 403-408 (1992).
Grainger et al., "Tamoxifen Decreases the Rate of Proliferation of Rat Vascular Smooth Cells in Culture by Inducing the Production of Transforming Growth Factor b", Biochem. J., 294, 109-112 (1993).
Grainger et al., "Proliferation of Human Smooth Muscle Cells Promoted by Lipoprotein (a)", Science, 260, 1655-1658 (1993).
Hanke et al., "Inhibition of Cellular Proliferation After Experimental Balloon Angioplasty by Low-Molecular-Weight Heparin", Circulation, 85, 1548-1556 (Apr. 1992).
Henriksson et al., "Hormonal Regulation of Serum Lp (a) Levels", J. Clin. Invest., 89, 1166-1171 (Apr. 1992).
Hofmann et al., "Enhancement of the Antiproliferative Effect of cis Diamminedichloroplatinum(II) and Nitrogen Mustard by Inhibitors of Protein Kinase C", Int. J. Cancer, 42, 382-388 (1988).
Hwang et al., "Effects of Platelet-Contained Growth Factors (PDGF, EGF, IGF-1, and TGF-.beta.) on DNA Synthesis in Porcine Aortic Smooth Muscle Cells in Culture", Exp. Cell Res., 200, 358-360 (1992).
Jordan, "Long-Term Tamoxifen Therapy to Control or to Prevent Breast Cancer: Laboratory Concept to Clinical Trials", Hormones Cell Biology and Cancer: Perspectives and Potentials; Alan R. Liss, Inc.; pp. 105-123 (1988).
Kirschenlohr et al., "Adult human aortic smooth muscle cells in culture produce active TGF-.beta.", Am. J. Physiol., 261, C571-C576 (Aug. 1993).
Knabbe, C. et al., "Induction of Transforming Growth Factor .beta. by the Antiestrogens Droloxifene, Tamoxifen, and Toremifene in MCF-7 Cells", Am. J. Clin. Oncol., 14, pp. S15-S20 (1991).
Koff et al., "Negative Regulation of G1 in Mammalian Cells: Inhibition of Cyclin E-Dependent Kinase by TGF-.beta.", Science, 260, 536-538 (Apr. 23, 1993).
Lefer et al., "Mechanisms of the Cardioprotective Effect of Transforming Growth Factor .beta..sub.1 Feline Myocardial Ischemia and Reperfusion", PNAS (USA), 90, 1018-1022 (Feb. 1993).
Lefer, "Role of Transforming Growth Factor .beta. is cardioprotection of the ischemic-reperfused myocardium", Growth Factors and the Cardiovascular System, P. Cummins, ed., Kluwer Acedemic Publishers, pp. 249-260 (1993).
Levy et al., "Drug Release From Submicronized O/W Emulsion: A New In Vitro Kinetic Evaluation Model", International Journal of Pharmaceutics, 66, 29-37 (1990).
Li et al., "Structure and Dynamics of Microemulsions Which Mimic the Lipid Phase of Low-Density Lipoproteins", Biochimica et Biophysica Acta, 1042, 42-50 (1990).
Liu et al, "Restenosis After Coronary Angioplasty-Potential Biologic Determinants and Role of Internal Hyperplasia", Circulation, 79, 1374-1387 (Jun. 1989).
Love et al., "Effects of Tamoxifen on Cardiovascular Risk Factors in Postmenopausal Women", Annals of Internal Medicine, 115, 860-864 (Dec. 1, 1991).
Love et al., "Effects of Tamoxifen Therapy on Lipid and Lipoprotein Levels in Postmenopausal Patients with Node-Negative Breast Cancer", J. Natl. Cancer Inst., 8
Grainger David J.
Metcalfe James C.
Weissberg Peter L.
Henley III Raymond
NeoRx Corporation
LandOfFree
Prevention and treatment of pathologies associated with abnormal does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prevention and treatment of pathologies associated with abnormal, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prevention and treatment of pathologies associated with abnormal will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-679097